Viracta Therapeutics Overview
- Year Founded
-
1998
- Status
-
Public
- Employees
-
38
- Stock Symbol
-
VIRX
- Investments
-
2
- Share Price
-
$0.01
- (As of Monday Closing)
Viracta Therapeutics General Information
Description
Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. The product candidate of the company is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people with organ transplants.
Contact Information
Website
www.viracta.comCorporate Office
- 2533 South Coast Highway 101
- Suite 210
- Cardiff, CA 92007
- United States
Corporate Office
- 2533 South Coast Highway 101
- Suite 210
- Cardiff, CA 92007
- United States
Viracta Therapeutics Stock Performance
As of 14-Jul-2025, Viracta Therapeutics’s stock price is $0.01. Its current market cap is $401K with 39.7M shares.
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.01 | $0.01 | $401K | 39.7M | 119K | -$1.10 |
Viracta Therapeutics Financials Summary
As of 30-Sep-2024, Viracta Therapeutics has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | 3,387 | (9,924) | (10,600) | 36,431 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (41,781) | (50,207) | (49,581) | (114,131) |
| Net Income | (43,289) | (51,058) | (49,197) | (114,762) |
| Total Assets | 21,958 | 56,692 | 95,991 | 108,552 |
| Total Debt | 16,911 | 25,556 | 25,155 | 5,478 |
Viracta Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Viracta Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Viracta Therapeutics Comparisons
Industry
Financing
Details
Viracta Therapeutics Competitors (56)
One of Viracta Therapeutics’s 56 competitors is Blueprint Medicines, a Formerly VC-backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Blueprint Medicines | Formerly VC-backed | Cambridge, MA | ||||
| Cytodyn | Formerly Angel backed | Vancouver, WA | ||||
| NexImmune | Formerly VC-backed | Gaithersburg, MD | ||||
| Kite Pharma | Formerly VC-backed | Santa Monica, CA | ||||
| Peloton Therapeutics | Formerly VC-backed | Dallas, TX |
Viracta Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Viracta Therapeutics Patents
Viracta Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-10953011-B2 | Methods of treating virally associated cancers with histone deacetylase inhibitors | Active | 31-May-2019 | ||
| US-20200375990-A1 | Methods of treating virally associated cancers with histone deacetylase inhibitors | Active | 31-May-2019 | ||
| US-20220226322-A1 | Methods of treating virally associated cancers with histone deacetylase inhibitors | Inactive | 31-May-2019 | ||
| US-20190175589-A1 | Pharmaceutical formulations, processes for preparation, and methods of use | Inactive | 09-Nov-2017 | ||
| US-20200390764-A1 | Pharmaceutical formulations, processes for preparation, and methods of use | Inactive | 09-Nov-2017 | A61K31/4985 |
Viracta Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Viracta Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Viracta Therapeutics Investments & Acquisitions (2)
Viracta Therapeutics’s most recent deal was a Merger/Acquisition with Sunesis. The deal was made on 24-Feb-2021.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Sunesis | 24-Feb-2021 | Merger/Acquisition | Biotechnology | ||
| Chroma Therapeutics (VRx-3996 Drug Development and Research Rights) | 30-Nov-2016 | Corporate Asset Purchase | Buildings and Property |
Viracta Therapeutics ESG
Risk Overview
Risk Rating
Updated April, 01, 2022
32.78 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,912
Rank
Percentile
Pharmaceuticals
Industry
of 965
Rank
Percentile
Biotechnology
Subindustry
of 443
Rank
Percentile
Viracta Therapeutics FAQs
-
When was Viracta Therapeutics founded?
Viracta Therapeutics was founded in 1998.
-
Where is Viracta Therapeutics headquartered?
Viracta Therapeutics is headquartered in Cardiff, CA.
-
What is the size of Viracta Therapeutics?
Viracta Therapeutics has 38 total employees.
-
What industry is Viracta Therapeutics in?
Viracta Therapeutics’s primary industry is Drug Discovery.
-
Is Viracta Therapeutics a private or public company?
Viracta Therapeutics is a Public company.
-
What is Viracta Therapeutics’s stock symbol?
The ticker symbol for Viracta Therapeutics is VIRX.
-
What is the current stock price of Viracta Therapeutics?
As of 14-Jul-2025 the stock price of Viracta Therapeutics is $0.01.
-
What is the current market cap of Viracta Therapeutics?
The current market capitalization of Viracta Therapeutics is $401K.
-
Who are Viracta Therapeutics’s competitors?
Blueprint Medicines, Cytodyn, NexImmune, Kite Pharma, and Peloton Therapeutics are some of the 56 competitors of Viracta Therapeutics.
-
What is Viracta Therapeutics’s annual earnings per share (EPS)?
Viracta Therapeutics’s EPS for 12 months was -$1.10.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
